Last reviewed · How we verify
Capecitabine plus bevacizumab
Capecitabine is a prodrug that converts to fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, while bevacizumab is a monoclonal antibody that blocks VEGF to inhibit tumor angiogenesis.
Capecitabine is a prodrug that converts to fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, while bevacizumab is a monoclonal antibody that blocks VEGF to inhibit tumor angiogenesis. Used for Metastatic colorectal cancer, Metastatic breast cancer.
At a glance
| Generic name | Capecitabine plus bevacizumab |
|---|---|
| Also known as | capecitabine, Avastin |
| Sponsor | GERCOR - Multidisciplinary Oncology Cooperative Group |
| Drug class | Antimetabolite plus monoclonal antibody |
| Target | Thymidylate synthase (capecitabine); VEGF (bevacizumab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Capecitabine is metabolized to 5-fluorouracil, which inhibits thymidylate synthase and incorporates into DNA/RNA to impair cancer cell replication. Bevacizumab binds vascular endothelial growth factor (VEGF), preventing its interaction with VEGF receptors on endothelial cells and thereby blocking new blood vessel formation that tumors depend on for growth and metastasis. The combination provides complementary cytotoxic and anti-angiogenic effects.
Approved indications
- Metastatic colorectal cancer
- Metastatic breast cancer
Common side effects
- Hand-foot skin reaction
- Diarrhea
- Nausea
- Fatigue
- Hypertension
- Proteinuria
- Bleeding
- Thromboembolism
Key clinical trials
- Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (PHASE3)
- A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. (PHASE2, PHASE3)
- A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) (PHASE2)
- Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) (PHASE1)
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
- A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: